

Personal Information

Clelia Madeddu

📍 Department of Medical Sciences and Public Health, University of Cagliari, SS 554, km 4,500, junction Sestu, 09042 Monserrato, Cagliari
☎ +390706754228

✉ clelia.madeddu@unica.it

🔗 [HTTPS://WWW.RESEARCHGATE.NET/PROFILE/CLELIA_MADEDDU](https://www.researchgate.net/profile/Clelia_Madeddu); Scopus Author's ID 6602330731

CURRENT ACADEMIC AND PROFESSIONAL POSITION

Current Academic Position: From October 2018 to date, Associate Professor in Medical Oncology (06/D3/Scientific Disciplinary Sector MED/06), at the University of Cagliari, Department of Medical Sciences and Public Health

Other academic positions:

- Coordinator of the Class of Nursing Professions since July 2024
- Member of the Erasmus Commission, Faculty of Medicine and Surgery, University of Cagliari since September 2013
- Member of the Council of the Faculty of Medicine and Surgery, University of Cagliari since September 2020
- Member of the Academic Senate, University of Cagliari from July 2021 to July 2024
- Member of the Board of Professors of the PhD in Molecular and Translational Medicine, University of Cagliari since September 2013

Previous academic role

From 01/07/2005 to October 2018 Researcher (Assistant Professor) at the University of Cagliari, Department of Medical Sciences and Public Health.

Current healthcare work position:

From 01/07/2005 to date Physician Specialist in Medical Oncology, at the Complex Unit of Medical Oncology of the "Azienda Ospedaliero Universitaria" of Cagliari, University Hospital Duilio Casula in Monserrato.

Other current professional positions:

- Head of the High Specialization Project in "Multidisciplinary Management of Gynecological Neoplasms" lasting five years starting from 03/09/2020 and still in progress (resolution no. 1087 of 03/09/2020 adopted by the Director General of the AOU Cagliari)
- Member of the Regional Oncology Commission (DECREE N. 2 OF 31.01.2023) of the Sardinian Region

TRAINING ACTIVITY

- Degree in Medicine and Surgery at the University of Cagliari on 20/12/1999 with a grade of 110 out of 110, discussing the thesis "Role of inflammatory cytokines in the induction of neoplastic cachexia: cytokines and leptin in the peripheral blood of advanced cancer patients."
- Qualification to practice the profession in Medicine and Surgery in 2000 (registration number 909 as of 29/12/2000).
- Specialization in Medical Oncology obtained on November 18, 2004 at the School of Specialization in Medical Oncology, Faculty of Medicine and Surgery, University of Cagliari with a grade of 50/50 laude.
- Completion of the Oncology Preceptorship Program at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, on October 23-27, 2000
- Course in Medical Statistics and Clinical Epidemiology, 8 May 2001, Arborea, Oristano
- Theoretical/practical workshop "Cytometric Bead Array" of flow cytometric analysis in immunology at the Laboratory of Immunology, University of Cagliari in July 2003.
- Second level National Master in Immuno-oncology at the NIBIT Siena Foundation, 23-24 September 2016
- Participation in the Training Course in Evaluating and Negotiating in Oncology from the SDA Bocconi School of Management Campus 17/18 May and 7/8 June 2023

- Participation in the Advanced Training Course: "EXPERTS IN THE EVALUATION AND FACILITATION OF REGIONAL ONCOLOGY NETWORKS - Good Practices for the Governance of Oncology Networks - organized by AGENAS- National Agency for Regional Health Services from 08/03/2023 to 04/07/2023

SCIENTIFIC AND RESEARCH ACTIVITIES

Impact of overall scientific output

- Clelia Madeddu is the author of numerous scientific articles published in international peer-reviewed journals:
- 285 publications according to the ISIWEB database with a total number of citations of 6383 and **total h index of 44** (<https://www.webofscience.com/wos/allldb/citation-report/f8c22fb2-1383-4d67-b07e-9f3c8e396f2d-cc2240aa>)
- 164 articles as per the Scopus database with a total number of citations from other authors equal to 5973, h index 43 (<https://www.scopus.com/authid/detail.uri?authorId=6602330731>)
- 276 publications according to the ResearchGate database with h index 46, number of citations 7253 (https://www.researchgate.net/profile/Clelia_Madeddu);
- 157 articles in extenso according to PubMed (<https://pubmed.ncbi.nlm.nih.gov/>)
- over 300 publications according to the Google scholar portal with 7288 citations, h index 48 https://scholar.google.it/citations?view_op=list_works&hl=it&user=21SEDcgAAAAJ

Areas of scientific research

Clelia Madeddu has been actively and continuously carrying out research activities both in preclinical and translational laboratory (in vitro and ex vivo studies) and clinical research activities, mainly focused on the following topics in detail:

immunology and immunotherapy of solid tumors; gynecological neoplasms; pathogenesis and prognostic factors of hormone-dependent female cancers; pharmacotherapy of solid tumors; mutational and precision oncology; pathophysiology and therapy of symptoms associated with cancer and its treatments, with particular reference to cancer patients in advanced stages of disease; pathophysiology and therapy of neoplastic cachexia; pathophysiology and therapy of cancer anemia; pathogenetic mechanisms and strategies for the prevention and treatment of cardiotoxicity induced by antineoplastic treatments; multidisciplinary and integrated approach to oncological pathologies.

This research activity has been the subject of scientific publications in international peer-reviewed journals, in the form of original articles, reviews, case-reports, as well as book chapters, oral presentations and posters at international and national conferences.

Participation in international, national and local research projects, eligible for funding on the basis of competitive calls for peer review

- Principal Research Collaborator of the project entitled "Cost-effectiveness of innovative, non-pharmacological strategies for early detection, prevention and tailored care of depressive disorders among cancer patients: Transcranial Magnetic Stimulation and Virtual Reality based Cognitive Remediation" funded under the PNRR call: M6/C2_CALL 2022 (PNRR-MAD-2022-12375899).
- Research Collaborator within the Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches for Precision Medicine (HEAL ITALIA) project funded by the National Recovery and Resilience Plan (PNRR) according to the project proposal approved by the MUR (project code PE000019) with concession decree no. 1559 prot 11/10/2022.
- Principal Investigator of the two-year research project PNRR 2022 entitled "Role of microbiota and proteomic microbiota in patients with hepatocellular cancer candidates to immunotherapy; Predictive and prognostic role" (code P2022AYTAK) admitted to the final evaluation with a score of 73/100.
- Head of the Clinical Trial observational study "Alcohol consumption is a risk factor for breast cancer: assessment of awareness of this risk factor", according to AOU Cagliari company resolution no. 236 of 14/02/2020, as part of the research project entitled "Alcohol and other modifiable risk factors for breast cancer" funded by the Foundation of Sardinia, call for annual prevention projects "Public Health, Preventive and Rehabilitative Medicine Sector" Year 2022;
- Participant in the research project entitled "[MIMOSA] MicrobioMe and plasma redOx status evaluation in women with breaSt cancer: potential correlation with Alcohol consumption and other lifestyle risk factors" funded under the two-year call FdS Call - Call

2022

- Participation as Head of Laboratory activities and Participating Unit in the study entitled: "Analysis of prognostic and predictive factors in patients with advanced ovarian cancer: observational study. Data fairing sub-study. Clinical research sub-study on the prognostic and predictive role of macrophage polarization of the tumor microenvironment in ovarian cancer (PROTAM trial)". Protocol Code: PROTAM. Promoter/Sponsor: ARNAS "G. Brotzu"
- Investigator Prof. Antonio Macciò, funded by Sardegna Ricerche as part of the Call "FAIR - enhancement of Independent and FAIR clinical research" DET DG 1644 PST OF 16/12/2019 and DET DG 8 of 07/01/2020.
- Head of the Biomedical Research Project entitled "Biomedical project code RF-2011-02352423 entitled "Advanced ovarian cancer as an immunologic, endocrine and metabolic disorder. Translational research for the development of a targeted approach of advanced ovarian cancer-related symptoms" code RF-2011-02352423 within the MUR Finalized Research Call for 2013, admitted to the evaluation with a final score of 13 out of 45 (5 best score – 45 worst score)
- Participation in Research Project n.2021. 1517 (Prot.U951.2021/AI.931.BE) entitled "Spiritual and psychosocial well-being and prognosis in patients with gynecological neoplasms", funded by the "Banco di Sardegna Foundation" from 12/02/2021 to 12/02/2022.
- Participation in the Research Project no. 2014.1883 entitled "Advanced ovarian cancer as an immunological, endocrine and metabolic disorder. Translational research project for the development of a targeted integrated approach to symptoms associated with cancer" funded by the "Banco di Sardegna Foundation" for the two-year period 2014-2015
- Participant in the National Research Program funded by MIUR, PRIN 2006-2008 entitled "Randomized phase III clinical trial to evaluate the efficacy and tolerability of an integrated treatment (dietary, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress"
- Participant in the National Research Project funded by MIUR, PRIN 2004-2006 entitled "Anorexia/cachexia and oxidative stress related to cancer: innovative dietary, pharmaco-nutritional and pharmacological treatment approach".
- Coordinator of the Scientific Research Project entitled "Evaluation of early myocardial injury induced by trastuzumab/lapatinib in patients with breast cancer. Perspectives of pharmacological prevention" funded by the University of Cagliari as part of the Local Scientific Research Projects-Area 06-Medical Sciences-financial year 2009
- Coordinator of the Local Scientific Research Project-Area 06-Medical Sciences-University of Cagliari - financial year 2007- entitled "Phase II randomized clinical trial with 5 treatment arms in patients with neoplastic anorexia/cachexia syndrome" (prot. 8017 of 30/06/2008).
- Coordinator of the Local Scientific Research Project-Area 06-Medical Sciences-University of Cagliari - financial year 2006- entitled "Epirubicin cardiac dysfunction by tissue Doppler: correlation with inflammatory parameters. Phase II study of preventive treatment" (prot. 84 of 20/03/2007).
- Head of the Clinical Trial observational study entitled "Alcohol consumption is a risk factor for breast cancer: assessment of awareness of this risk factor" approved by AOU Cagliari company resolution no. 236 of 14/02/2023, active in the recruitment phase. This clinical study is part of a Research Project entitled "Alcohol and other modifiable risk factors for breast cancer" funded by the Foundation of Sardinia, as part of the annual prevention projects "Public Health, Preventive and Rehabilitation Medicine Sector" Year 2022
- Principal Research Collaborator of the national project entitled "Cost-effectiveness of innovative, non-pharmacological strategies for early detection, prevention and tailored care of depressive disorders among cancer patients: Transcranial Magnetic Stimulation and Virtual Reality based Cognitive Remediation" funded under the PNRR call: M6/C2_CALL 2022 (PNRR-MAD-2022-12375899 Project code), active in the recruitment phase;
- Research Collaborator within the Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches for Precision Medicine (HEAL ITALIA) project funded by the National Recovery and Resilience Plan (PNRR) according to the project proposal approved by the MUR (project code PE0000019) with concession decree no. 1559 prot 11/10/2022.

Responsibility for scientific studies and research including positions as Principal Investigator and/or Coinvestigator of national and international clinical trials entrusted by qualified public or private institutions

- Head of the National Clinical Trial "Nivolumab in Oncology Practice Data collection on safety and effectiveness. NIVO-COLLECT protocol code", approved by AOU Cagliari company resolution no. 617 of 11/06/2019;
- Responsible for the international multicenter clinical study Prot 1200.43 LUX-Head and Neck 1, approved by AOU Cagliari company resolution no. 924 of 22/11/2012;
- Co-Investigator of the clinical study "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)", active in the recruitment phase;
- Co-investigator of the clinical trial "Ambispective observational study describing the diagnosis and treatment patterns in clinical practice of adults with BRAF V600E-mutated metastatic non-small cell lung cancer, to evaluate the treatment efficacy and quality of life OCTOPUS", active in the recruitment phase;
- Co-investigator of the clinical study "Clinical performance study for the use of the Vysis MET FISH probe kit for the identification of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer and MET amplification, who experienced progression during treatment with osimertinib for the AstraZeneca phase III SAFFRON study (D5087C00001)", active in the recruitment phase;
- Co-investigator of the clinical study entitled "A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)";
- Co-investigator of the clinical trial "A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation";
- Co-investigator of the clinical trial "R2810-ONC-16113 A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), IPILIMUMAB (ANTI-CTLA-4 ANTIBODY), AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 <50%";
- Co-investigator of the clinical trial "A randomized, phase 3, open-label study of combinations of REGN2810 (anti PDL antibody), platinum-based doublet chemotherapy and ipilimumab (anti CTLA-4 antibody), versus pembrolizumab as monotherapy in first-line treatment of patients with advanced or metastatic non-small cell lung cancer with tumors expressing PD-L1 >50%";
- Coordinator of the research activity of the student Laura Bosch Pérez for the duration of about 9 months at the Laboratory of Medical Oncology, Department of Internal Medical Sciences of the University of Cagliari, as part of the Research Project entitled "Techniques and methodology for the study of inflammation, proliferative and functional capacity of tumor and immune cells of the ovarian cancer microenvironment (Tècniques i metodologia en l'estudi de la inflamació, del creixement i proliferació de cèl·lules tumorals en dones amb càncer d'ovari)" conducted in collaboration with the University of Barcelona, Spain.
- Coordinator of the scientific and research activities of Dr. Itaru Omoto from Japan, University of Kagoshima, winner of a grant funded by the "Japan Society for the Promotion of Science" for the conduct of a project entitled "Experimental models of cancer cachexia" lasting 9 months at the Department of Medical Sciences M. Aresu, University of Cagliari from 06/2012 03/2013
- Tutor and Head of Research Projects of PhD students enrolled in the PhD in Molecular and Translational Medicine, "Molecular and Translational Medicine" Ph.D. Program accredited by the Ministry, at the University of Cagliari from 2014 to date.
- Appointed by the Council of the Department of Medical Sciences Mario Aresu of the University of Cagliari as Head of the Laboratory of Medical Oncology from 2013 to 2015. At which clinical diagnostics, translational research and teaching activities were carried out, and to which graduate biologists have belonged as scholarship holders/research fellows under contract with the University of Cagliari, on funds from national and regional research projects for the performance of research activities related to various funded research programs (AIRC Project IG 8679 entitled Early trastuzumab/lapatinib-induced myocardial dysfunction; Master & Back Project 2011-2012 Sardinia Region), as well as PhD students

belonging to the PhD in "Molecular and Translational Medicine".

TEACHING ACTIVITY	- Teaching activity at Master's Degree Courses in Medicine and Surgery, Degree Courses in Health Professions, Post-Graduate Specialization Courses and University Masters of I and II level:
From 01/09/2013 to date	1) Teaching of Medical Oncology at the Master's Degree Course in Medicine and Surgery of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2013 to date (A.Y. 2013-2014; A.Y. 2014-2015; A.Y. 2017-2018, A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2023-2024);
From 01/09/2017 to date	2) Teaching of Medical Oncology in the Integrated Course of Nursing and Specialist Surgery at the Degree Course in Nursing (qualifying for the Health Profession of Nurse)-Canale di Nuoro of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2017 to date (A.Y. 2017-2018, 2018-2019, 2019-2020, 2020-2021, 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/09/2018 to date	3) Teaching of Medical Oncology as part of the Integrated Course of "Clinical Specialties" at the Degree Course in Health Care (qualifying for the health profession of health assistant) of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2018 to date (A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/09/2012 to 01/09/2013	4) Teaching of Medical Oncology in the Integrated Course of "Methodology and rehabilitation technique of visceral and special disabilities" at the Degree Course in Physiotherapy (qualifying for the health profession of physiotherapist) of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2012 to 01/09/2013 (A.Y. 2012-2103);
From 01/09/2013 to 01/09/2019	5) Teaching of Medical Oncology in the Integrated Course of "Rehabilitation of Visceral Disabilities" at the Degree Course in Physiotherapy (qualifying for the health profession of physiotherapist) of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2013 to 01/09/2019 (A.Y. 2013-2104, A.Y. 2016-2017, A.Y. 2017-2018, A.Y. 2018-2019);
From 01/09/2019 to date	6) Teaching of Medical Oncology in the Integrated Course of "Internal and Geriatric Disabilities" at the Degree Course in Physiotherapy (qualifying for the health profession of physiotherapist) of the Faculty of Medicine and Surgery from 01/09/2019 to date (A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024)
From 01/09/2012 to 01/09/2018	7) Teaching of Medical Oncology in the Integrated Course of Clinical Laboratory at the Degree Course in Biomedical Laboratory Techniques (qualifying for the health profession of biomedical laboratory technician) of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2012 to 01/09/2018 (A.Y. 2012-2013, A.Y. 2014-2015, A.Y. 2016-2017, A.Y. 2017-2018);
From 01/09/2012 to 01/09/2013	8) Teaching of Medical Oncology in the Integrated Course of "Principles of Oncology, Senology, Sexology and Endocrinology" at the Degree Course in OBSTETRICS (qualifying for the health profession of midwifery) of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2012 to 01/09/2013 (A.Y. 2012-2013);
From 01/09/2012 to 01/09/2013	9) Teaching of "Progress in Oncology and Palliative Care" at the Master's Degree Course in Nursing and Midwifery Sciences of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2012 to 01/09/2013 (A.Y. 2012-2013);
From 01/09/2012 to 01/09/2014	10) Teaching of Medical Oncology in the Integrated Course "Evidence-based Nursing Sciences" at the Master's Degree Course in Nursing and Midwifery Sciences of the Faculty of Medicine and Surgery from 01/09/2012 to 01/09/2014 (A.Y. 2012-2013, A.Y. 2013-2014);
From 01/09/2013 to 01/09/2015	11) Teaching of Medical Oncology in the Integrated Course "Endocrine-metabolic, cardio-respiratory and oncological pathology" at the Bachelor's Degree Course in Science and Technique of Preventive and Adapted Physical Activity of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2013 to 01/09/2015 (A.Y. 2013-2014, A.Y. 2014-2015);
From 01/11/2006 to 01/11/2012	12) Lecturer in Medical Oncology at the School of Specialisation in Medical Oncology of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2006 to 01/11/2012 (A.Y. 2006-2207, A.Y. 2007-2008, A.Y. 2008-2009, A.Y. 2009-2010, A.Y. 2010-2011, A.Y.

	2011-2012)
From 01/11/2018 to date	13) Teaching of Medical Oncology at the School of Specialization of Medical Oncology of the Faculty of Medicine and Surgery of the University of Cagliari, as Associate Professor of Medical Oncology from 01/11/2018 to date (A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2016 to today	14) Teaching of Medical Oncology at the School of Specialization of Medical Genetics of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2006 to date (A.Y. 2006-2007, A.Y. 2007-2008, A.Y. 2008-2009, A.Y. 2009-2010, A.Y. 2010-2011, A.Y. 2011-2012, A.Y. 2012-2013, A.Y. 2013-2014, A.Y. 2014-2015, A.Y. 2015-2016, A.Y. 2016-2017, A.Y. 2017-2018, A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2020 to date	15) Teaching of "Tumor Immunology" at the School of Specialization of Allergology and Clinical Immunology of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2020 to date (still ongoing) (A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2020 to date	16) Teaching of Medical Oncology at the School of Specialization of Hematology of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2020 to date (still ongoing) (A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2020 to date	17) Teaching of "Internal medicine of the most common pathologies: Oncology" at the School of Specialization of Internal Medicine of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2020 to date (still in progress) (A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2010 to present	18) Teaching of "Nutritional approach for oncological pathologies" at the School of Specialization of Food Sciences of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2010 to date (still ongoing) (A.Y. 2010-2011, A.Y. 2011-2012, A.Y. 2012-2013, A.Y. 2013-2014, A.Y. 2014-2015, A.Y. 2015-2016, A.Y. 2016-2017, A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2020 to date	19) Teaching of "Medical Oncology" at the School of Specialization of Anesthesia and Resuscitation of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2020 to date (still ongoing) (A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2010 to present	20) Teaching of "Medical Oncology" at the School of Specialization of Geriatrics of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2010 to date (still ongoing) (A.Y. 2010-2011, A.Y. 2011-2012, A.Y. 2012-2013, A.Y. 2013-2014, A.Y. 2014-2015, A.Y. 2015-2016, A.Y. 2016-2017, A.Y. 2017-2018, A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/11/2017 to date	21) Lecturer in Medical Oncology at the School of Specialisation in Gynecology and Obstetrics of the Faculty of Medicine and Surgery of the University of Cagliari from 01/11/2017 to date (still ongoing) (A.Y. 2017-2018, A.Y. 2018-2019, A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023, A.Y. 2023-2024);
From 01/09/2019 to date	22) Teaching of Medical Oncology at the 1st and 2nd level Master in "Palliative Care and Pain Therapy" of the Faculty of Medicine and Surgery of the University of Cagliari from 01/09/2019 to date (still ongoing) (A.Y. 2019-2020, A.Y. 2020-2021, A.Y. 2021-2022, A.Y. 2022-2023 For n. hours 8/year, total hours 32 Address via Università 40;
From 01/09/2017 to 01/09/2020	23) Teaching "Cachexia and nutritional problems" at the 1st level University Master in "Palliative Care and Pain Therapy" of the Faculty of Medicine and Surgery of the University of Bologna, Academy of Sciences of Palliative Medicine from 01/09/2017 to 01/09/2020
From 17/07/2013 to date	25) Participation in the Board of Professors, in the context of PhDs accredited by the Ministry: Member of the Board of Professors of the Doctorate entitled: "MOLECULAR AND TRANSLATIONAL MEDICINE", at the University of CAGLIARI from 17/07/2013 to date (still in progress)
From 17/07/2013 to date	26) Tutor of PhD students enrolled in the PhD entitled "MOLECULAR AND

TRANSLATIONAL MEDICINE Ph.D. Program" at the University of Cagliari (from 17/07/2013 to date).

Other teaching or research positions at qualified foreign or supranational universities and research institutes:

- Appointment of Tutor Professor and Head of the Research Project entitled "Techniques and methodology for the study of inflammation, proliferative and functional capacity of tumor and immune cells of the ovarian cancer microenvironment (Tècniques i metodologia en l'estudi de la inflamació, del creixement i proliferació de cèl·lules tumorals en dones amb càncer d'ovari)" by the Faculty of Biology, of the University of Barcelona, Spain. The project involved the coordination of the research activity of the student Laura Bosch Pérez for the duration of about 9 months at the Laboratory of Medical Oncology, Department of Internal Medical Sciences of the University of Cagliari in the year 2015.
- Coordinator and Tutor of the research project entitled "Experimental models of cancer cachexia" funded by the "Japan Society for the Promotion of Science" and conducted at the Department of Internal Medical Sciences Mario Aresu, in collaboration with the University of Kagoshima, Japan, from June 2012 to March 2013.
- Lecturer (Lecturer) at the Degree in Biochemistry at the University of Barcelona, Spain

PARTICIPATION IN SCIENTIFIC CONFERENCES AT INTERNATIONAL AND NATIONAL LEVEL AS A SPEAKER or ORGANIZER

- 1) Speaker at the International Congress "EASL Liver Cancer Summit 2023" held in Estoril (Portugal) on 20-22 April 2023 with the report entitled "Management of cancer-treatment related fatigue and cachexia" as part of the Session "Multidisciplinary care of patients with liver cancer"
- 2) Speaker at the International Congress "The Sixth International Renal Meeting with Mayo Clinic in Sardinia" held in Cagliari on 29 May-2 June 2023 with the report entitled "Cachexia"
- 3) Speaker at the International Congress "VIROLOGY 2021" held online on 22 June 2021, with the oral report entitled "COVID-19 and cytokine storm syndrome: Can what we know about interleukin-6 in cancer be applied?"
- 4) Speaker at the SIOG 2018-International Society of Geriatric Oncology International Congress held in Amsterdam from 16 to 18 November 2018 with the following presentations: "Management of anorexia" and "Disturbance of taste and risk of malnutrition" in the session "Optimise nutritional strategies for excellent cancer care".
- 5) Speaker at the ESMO (European Society of Medical Oncology) International Congress, held in Vienna from 28 September to 2 October 2012, in the session "ESMO proffered paper session supportive- palliative care", with the presentation entitled: "Efficacy and safety of a two drug combination regimen for cancer- related cachexia in clinical practice"
- 6) Speaker at the 35th International Congress ESMO (European Society of Medical Oncology) held in Milan on 8-12 October 2010 with the presentation entitled "Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)"
- 7) Speaker at the International Scientific Conference "Immunotherapy in Oncology" held in Alcalá (Spain), Alcalá University, on 21-22 April 2005 with the lecture entitled: "Inflammation and cachexia".
- 8) Speaker at the International Scientific Conference "Immunotherapy in Oncology" held in Coimbra (Portugal) on 22-23 September 2005 with the lecture entitled: "Inflammation and cachexia"
- 9) Speaker at the National Refresher Course "The hot topics in ovarian and endometrial cancer" held in Rome on 23 June 2023 with the report entitled "Immunotherapy in endometrial cancer"
- 10) Speaker at the National Congress "New Hope - new horizons and new opportunities for the patients with ovarian cancer 2.0" held in Gaeta on 18-19 May 2023 with the report entitled "Use of checkpoint inhibitors and target therapy in endometrial cancer"
- 11) Speaker at the National Scientific Congress "Wide-angle, Focus on Supportive Therapies 2021" held in Bologna on 9 and 10 May 2022, with the report entitled "News in the treatment of anorexia".

- 12) Speaker at the National Scientific Congress "IV CONGRESSO GIOGER-Geriatric Oncology: a necessity for the third millennium" held in Pesaro on 23/25 May 2019 with the report "Nutritional support"
- 13) Speaker at the National Scientific Conference "Wide angle in Oncology. Focus on supportive therapies 2018" held in Bologna, 7-8 May 2018, with the report "Oral supplements" in the session "The nutrition of the cancer patient between hospital and territory".
- 14) Speaker at the National Scientific Conference "Wide angle in Oncology. Focus on supportive therapies 2017" held in Bologna on 8-9 May 2017, with the report entitled "Anorexia/cachexia".
- 15) Speaker at the National Scientific Conference MASTER COURSE IMI (Italian Melanoma Intergroup) entitled "MANAGEMENT OF THE PATIENT WITH MELANOMA: FROM RESEARCH TO THERAPY" held in Cagliari on 17-18 March 2017.
- 16) Speaker at the National Scientific Conference "Wide-angle in Oncology. Focus on supportive therapies 2015" held in Bologna on 11-12 May 2015, with the report entitled: "Anorexia/cachexia"
- 17) Speaker at the National Scientific Conference "7th Congress of Geriatric Oncology of Salento: Personalized treatment in the "non-fit" elderly, held in Lecce on 13-14 May 2016 with the report entitled: "Nutrition"
- 18) Speaker at the National Scientific Conference "NICSO Scientific Focus "Meeting on ongoing studies and future prospects" held in Milan on December 15, 2015, with the lecture entitled: "New drugs in the management of anorexia-cachexia"
- 19) Speaker at the "75th SIC National Congress" held in Rome on 13-15 December 2014, with the report entitled: "The problem of cardiotoxicity: definition, drugs, mechanisms"
- 20) Speaker at the National Scientific Conference "XIV National Congress of Medical Oncology" held in Rome on 27-29 October 2012, with the report: "Nutritional aspects" in the Educational Session "CONTINUITY OF CARE IN ONCOLOGY. THE CONTROL OF SYMPTOMS"

Speaker at the following Congresses/Courses at regional level:

- 21) Speaker at the "NeuroCampus" Congress held in Cagliari on 15 June 2023 with the report entitled "Oncological risk: the oncologist's point of view"
- 22) Speaker at the Congress "Molecular tumor board and new organizational scenarios in the Sardinia Region" held in Cagliari on 2 December 2022 with the report entitled "Pathogenic mutations of the BRCA1 and BRCA2 germ line: ovarian cancers".
- 23) Speaker at the Congress "Parp-inhibitors and treatment of the patient with ovarian cancer" held in Cagliari on 25 November 2022 with the report entitled "Survival in ovarian cancer: clinical result and its spiritual significance"
- 24) Speaker at the "LUNGONLINE 2022" Congress - Digital Meeting (FAD Sincrona) held on 14 November 2022 with the report entitled "State of art immunotherapy"
- 25) Speaker and member of the Faculty of the Congress "Melanoma today: from prevention to therapeutic approach" held in Sassari on 9 September 2022, with the report "Adjuvant treatment in patients at risk: state of the art".
- 26) Speaker at the Congress "1st Congress of Onco-Nephrology in Sardinia" held in Cagliari on 14-15 July 2022 with the report entitled "New frontiers of immunotherapy: efficacy and potential toxicity"
- 27) Speaker at the Congress "Simultaneous care-Summer edition 2022" Digital Meeting 5 July 2022 with the Lecture entitled "Neoplastic cachexia key to understanding the condition of the neoplastic patient"
- 28) Speaker at the Congress "Ovarian cancer: new therapeutic perspectives and the role of PARP inhibitors" held in Cagliari on 11 June 2022 with the report entitled "Synergism of action between cisplatin and PARP inhibitors: rationale and therapeutic perspectives"
- 29) Speaker at the regional meeting "Melanoma-Sliding Doors 2022" held in Cagliari on 26 February 2022.
- 30) Speaker at the Congress "Bone health in oncology: management of bone metastases" held in Abbasanta on 3 December 2021 with the report entitled "Pathophysiology of bone

metastases and impact of Skeletal Related Events"

31) Speaker at the "Breast Cancer Update 2021" Congress held in Cagliari on 20 November 2021 with the report entitled "Pregnancy and chemotherapy: fertility preservation"

32) Speaker at the Scientific Congress entitled "Nutrition and physical activity in the promotion and maintenance of well-being" held in Cagliari on 30 October 2021, with the report entitled "Physical activity and nutrition in the prevention of cancer".

33) Speaker at the "Lungonline 2021" Digital Meeting held on 11 October 2021, with the report entitled "Lecture: Immunotherapy and immunomodulation"

34) Speaker at the Scientific Congress entitled "Simultaneous Care: 2021 updates" held in webinar mode on 10 June 2021, with the report entitled "Key immunomodulation of simultaneous care".

35) Speaker at the Scientific Congress entitled "Covid-19 - A new challenge for Medicine" held online on 19 March 2021 with the presentation entitled "The risks of SARS-COV2 in cancer patients"

36) Speaker at the Scientific Conference entitled "Update on new strategies in tumor immunotherapy" held in Cagliari on June 26, 2020, with the report entitled "Inflammation, angiogenesis and new combination strategies".

37) Speaker at the scientific event entitled "DIRECT TO BRCA: CREATING TERRITORIAL NETWORKS ON BRCA TESTING", held in WEBINAR mode on 5 NOVEMBER 2020, with the report entitled "BRCA test at the diagnosis of non-borderline non-mucinous ovarian cancer and the role of PARP-Inhibitors".

38) Speaker at the SIOMMMS Regional Congress "Osteoporosis: which reality" held in Cagliari on 6-7 December 2019 with the report entitled "Adjuvant hormone therapy: the role of the oncologist".

39) Speaker at the Scientific Conference entitled "Breast Cancer Update 2019" held in Cagliari on 23 November 2019 with the report entitled "Inflammation, immunology and tumors".

40) Speaker at the Conference "The Role of the Endocrinologist in Oncology" held in Cagliari on 13 December 2019 with the report entitled "Target therapies: action and indication in thyroid carcinomas".

41) Speaker at the Conference "Mind, body and cancer" held in Cagliari on 6-7 December 2019 with the report entitled: "Can antiangiogenic therapy integrate immunotherapy pathways?"

42) Speaker at the Scientific Congress entitled "Simultaneous care: comparing experiences", held in Cagliari on 28 June 2019, with the report "Biological bases of simultaneous care".

43) Speaker at the Congress "FEMALE CANCERS AND SPORT: A KICK TO CANCER, INFORMATION DAY", held in Cagliari, 4 May 2019, with the report entitled "Nutrition as prevention and therapy"

44) Speaker at the Congress "Interdisciplinary Approach to Ovarian Cancer", held in Cagliari on 01 December 2018, with the report entitled "Biology of ovarian cancer".

45) Speaker at the Scientific Conference "Novelties in the therapy of ovarian and breast cancer: a road together" held in Cagliari on 25 November 2017, with the report entitled: "The tumor microenvironment and its role in the etiopathogenesis of breast and ovarian cancer"

46) Speaker at the Scientific Conference "Simultaneous Care in Oncology - New paradigms of supportive care" held in Cagliari on 20 October 2017, with the report entitled: "Nausea and vomiting from chemotherapy"

47) Speaker at the Scientific Conference "Focus on renal carcinoma: what news?" held in Cagliari on 27 September 2017, with the report entitled "Immunotherapy and renal carcinoma"

48) Speaker at the Scientific Conference "New paradigms of supportive therapy: emesis from oral antitumor therapy, the exemplary case of mTOR inhibitors", held in Cagliari on June 30, 2017, with the report entitled: "The mTOR pathway in antitumor treatment"

49) Speaker at the Scientific Congress "Regional Congress of Dermatology 2017" held in

Cagliari on 20 May 2017 with the report entitled: "New therapeutic perspectives in Melanoma" (Oncological Dermatology Session).

50) Speaker at the National Scientific Conference "Seste Giornate Sarde di Scienze Ostetriche e Ginecologiche" held in Alghero on 18-20 May 2017, with the report entitled: "Diet as a protective factor in oncology".

51) Speaker at the scientific conference entitled "Against the pain" held in Cagliari on 09-10 April 2017, with the report entitled: "Simultaneous Care in Oncology"

52) Speaker at the Course "Focus on melanoma therapy" held in Dolianova on 1 December 2016

53) Speaker at the Scientific Conference "Metastatic Castration-Resistant Prostate Cancer (mCRPC): Ra223 dichloride in clinical practice" held in Cagliari on 18 November 2016 with the report entitled: "Future prospects: Therapeutic associations and sequences"

54) Speaker at the Congress "Cardiological Days for Sardinia 2016" held in Cagliari on 7-8 October 2016, with the report entitled: "Pathophysiology of cardiotoxicity from Anthracyclines"

55) Speaker at the National Congress "From care to having care of women in the technological universe of Gynecology and Obstetrics" held in Cagliari on 13-16 July 2016, with the report entitled "Ovarian cancer: immunological therapy"

56) Participation as Moderator in the Congress "Therapy of solid tumors: focus on monoclonal antibodies" held in Cagliari on 27 May 2016.

57) Speaker at the Scientific Conference entitled "Il Focus on Head and Neck Cancer: Laryngeal Tumors" held in Cagliari on 16 April 2016, with the report entitled: "Nutritional Evaluation and Support"

58) Speaker at the Scientific Conference "SLIDING DOORS PROJECT. THE PERSONALIZED THERAPY OF OVARIAN CANCER" held in Cagliari on 02 March 2016

59) Speaker at the Scientific Conference "The centrality of antiangiogenic therapy in the treatment of ovarian cancer" held in Cagliari on 21 November 2015, with the report entitled: "Etiopathogenesis: role of the tumor microenvironment"

60) Speaker at the Scientific Conference "Relapsed ovarian cancer: Diagnostic framework and therapeutic strategies" held in Cagliari on 18 December 2015

61) Speaker at the Scientific Conference "Convegno AIOM Sardegna. Lifestyles, nutrition and cancer" held in Cagliari on 17 October 2015 with the report entitled: "Adipose tissue and breast cancer: a dangerous couple"

62) Speaker at the Scientific Conference "1st SARDINIAN DAY OF DERMATO-ONCOLOGY" held in Cagliari on 13 June 2015 with the report entitled: "Immunotherapy and Target Therapy"

63) Speaker at the Scientific Conference "QUINTE GIORNATE SARDE DI SCIENZE OBSTETRICE E GINECOLOGICA" held in Alghero on 21-23 May 2015, with the report entitled: "PCOS and cancer"

64) Speaker at the Congress "Cardiology Days for Sardinia 2014" held in Cagliari on 17-18 October 2014, with the report entitled: "The problem of cardiotoxicity: definition, drugs, mechanisms"

65) Speaker at the Scientific Conference "Practical course of gynecological and obstetric sciences" held in Cagliari on 10-12 July 2014, with the report entitled: "Tumor microenvironment in the etiopathogenesis and evolution of ovarian cancer"

66) Speaker at the Conference "Role of biological drugs in the therapy of ovarian cancer: from etiopathogenesis to the clinic" held in Cagliari on 22 November 2014, with the report entitled: "The tumor microenvironment in the evolution of ovarian cancer"

67) Speaker at the Scientific Conference "Symptoms associated with cancer" held in Cagliari on 28 November 2014, with the report entitled: "Role of biological drugs in the best protection of quality of life (colorectal cancer). Biological bases of targeted therapy"

68) Speaker at the Scientific Conference "Integration of the old with the new in the most modern cancer therapy" held in Sanluri on March 15, 2014, with the report entitled: "Patient biology and implications in cancer therapy"

69) Speaker at the Scientific Conference "Updates in Oncology" held in Cagliari on 16 November 2013, with the report entitled: "Nutrition and tumors: reading"

- 70) Speaker at the Scientific Conference "VIII SIPREC Regional Course "Cardiovascular diseases and neoplasms: risk factors in common?" held in Cagliari on 23 November 2013, with the report entitled: "Stress and tumors"
- 71) Speaker at the Scientific Conference "Breast cancer: From prevention to support" held in Cagliari on 11 May 2013, with the report entitled: "New drugs, new toxicities: management of the patient in treatment with oral therapy at home"
- 72) Speaker at the National Scientific Conference "Fourth Sardinian Days of Obstetric and Gynecological Sciences" held in Alghero on 15-18 May 2013, with the report entitled: "Nutraceuticals and menopause"
- 73) Speaker at the Scientific Conference "Updates in Oncology: Evolution in the personalization of oncological care: from target therapy to supportive therapies" held in Sardara on 17 November 2012, with the report "Inflammation and cancer: role of biological therapies"
- 74) Speaker at the Scientific Conference "Pathways of diagnosis and therapy in ovarian cancer" held in Sardara on 26 June 2012
- 75) Speaker at the Scientific Conference "Advanced Breast Cancer and Bone Metastases: Innovation and Gold Standard of Treatment" held in Oristano on 25 September 2012, with the report entitled: "Treatment monitoring"
- 76) Speaker at the Scientific Conference "Supportive therapies in oncology" held in Aritzo on 08 October 2011, with the report entitled: "Integrated nutrition: when and why"
- 77) Speaker at the Scientific Conference "V Congress of the Department of Internal Medical Sciences Mario Aresu" held in Cagliari on 16-17 December 2011
- 78) Speaker at the Course "National and international guidelines for the treatment of bone metastases" held in Cagliari on 10 June 2011
- 79) Speaker at the Scientific Conference "Therapy of ovarian cancer recurrence: regional consensus meeting" held in Oristano on 19 March 2011, with the report entitled: "Principles of platinum-resistance and refractoriness: current therapeutic choices"
- 80) Speaker at the Scientific Conference "Pleuropulmonary tumors: from the state of the art to future developments" held in Guspini on 11 December 2010, with the report entitled: "Nutrition and lung cancer"
- 81) Speaker at the Scientific Conference "Innovations in the treatment of breast cancer" held in Assemmini on 23 October 2010
- 82) Speaker at the Scientific Conference "The global care of the neoplastic patient: the contribution of medical oncology" held in Villagrande Strisaili on 20 March 2010 with the report entitled "Adipose tissue and neoplasms"
- 83) Speaker at the scientific conference "Optimizing anticancer therapy. Research contributions" held in Fordongianus on 03 July 2010, with the report entitled: "Nutritional support of neoplastic cachexia"
- 84) Speaker at the Scientific Conference "IV Congress of the Department of Internal Medical Sciences Mario Aresu", sponsored by the Italian Society of Medical Oncology, held in Cagliari on 11-12 December 2009
- 85) Speaker at the Scientific Conference "New perspectives in the prevention and treatment of hormone-dependent breast cancer" held in Guspini on December 4, 2009, with the report entitled: "Adipose tissue: endocrine organ"
- 86) Speaker at the Scientific Conference "Diagnostics and multidisciplinary treatment of lung cancer" held in Cagliari on 19-20 June 2009, with the report entitled: "Clinical-diagnostic problems of the patient with lung cancer"
- 87) Speaker at the Scientific Conference "Hormone-dependent tumors in women: from biology to the clinic" held in Cagliari on June 30, 2007
- 88) Speaker at the Scientific Conference "Updates in oncology: tumors of the elderly" held in Bari Sardo on 16-17 November 2007
- 89) Speaker at the Scientific Conference "The humanization of care in oncology" held in Sardara on June 23, 2007
- 90) Speaker at the Scientific Conference "II Congress of the Department of Internal Medical Sciences Mario Aresu" held in Cagliari on 14-15 December 2007
- 91) Speaker at the Scientific Conference "Humanization in oncology: attention to the

patient as a subject of care" held in Cagliari on May 29, 2006

92) Speaker at the Scientific Conference "New diagnostic aspects and new therapeutic choices in cancer patients" held in Cagliari on 14 October 2006

93) Scientific Secretariat of the accredited Scientific Conference entitled "Mind, Body and Cancer", held in Cagliari, at the Aula Magna of the Pontifical Sardinian Regional Seminary on 6 and 7 December 2019.

94) Scientific Secretariat of the accredited Scientific Conference entitled "Mutated BRCA tumors: new therapeutic perspectives" held in Cagliari, Conference Room Lazzaretto Sant'Elia, on 22 April 2017.

95) Scientific Secretariat of the Scientific Conference "Survival in oncology: clinical result and its spiritual significance" held in Cagliari at the Archiepiscopal Seminary on 12 November 2016

96) Scientific Secretariat of the Scientific Conference "The centrality of antiangiogenic therapy in the treatment of ovarian cancer" held in Cagliari on 21 November 2015

97) Scientific Secretariat of the Scientific Conference entitled "Role of biological drugs in the therapy of ovarian cancer: from etiopathogenesis to the clinic" held in Cagliari on 22 November 2014

98) Scientific Secretariat of the Residential Training Course "Pathways of diagnosis and therapy in ovarian cancer" held in Sardara on 26 June 2012

99) Scientific Secretariat of the Scientific Conference "Therapy of ovarian cancer recurrence: regional consensus meeting" held in Oristano on 19 March 2011

100) - Scientific Secretariat of the National Scientific Conference entitled "Leptin and Women's Health" sponsored by the National Academy of Medicine held in Cagliari on 22 and 23 September 2005.

Direction or participation in Editorial Committees of Journals, editorial series, encyclopedias and treatises of recognized prestige

- Member of the Editorial Board of the international peer-reviewed journal "Scientific Reports" (impact factor 4.9)

- Associate Editor for the international peer-reviewed journal "International Journal of Immunopathology and Pharmacology" Impact Factor 3.5

-Associate Editor for the international peer-reviewed journal "Frontiers in Nutrition" (Impact Factor 6.576); <https://www.frontiersin.org/journals/nutrition/sections/clinical-nutrition>;

-Member of the Editorial Board of the international peer-reviewed journal Oncology Letters (Impact Factor 2.967) since 2021;

- Participation in the Editorial Board as "Topical Advisory Panel Member" of the international peer-reviewed journal International Journal of Molecular Sciences (Impact Factor 5.923);

-Participation in the Editorial Board as Guest Editor of the international peer-reviewed journal Cancers (Impact Factor 6.639) Special Issue entitled "State-of-the-Art in Cancer Cachexia Diagnostic, Prognostic and Therapy", section "Cancer Pathophysiology";

-Participation in the Editorial Board as Guest Editor of the Special Issue entitled "Molecular Basis and Advances of Targeted Immunotherapy for Cancer" for the international peer-reviewed International Journal of Molecular Sciences (Impact Factor 5.923), Section Molecular Immunology;

-Participation in the Editorial Board as Guest Editor of the international peer-reviewed journal Diagnostics (Impact Factor 3.706), Special Issue entitled "Prognostic Role of White Blood Cells and Platelets Count Changes in Solid Tumors", section "Pathology and Molecular Diagnostics";

- Participation in the Editorial Committee as Guest Editor of the Special Issue "Biological and Molecular Mechanisms of Resistance and Tolerance during the Course of the Neoplastic Disease" for the international peer-reviewed International Journal of Molecular Sciences (Impact Factor 5.923), Section Molecular Oncology;

- Participation as Topic Editor of the Research Topic entitled "Importance of Body Composition Analysis in Clinical Nutrition" of the international peer-reviewed journal Frontiers in Nutrition (Impact Factor 6.576), Section Clinical Nutrition;

-Participation in the Editorial Board as Guest Associate Editor of the international peer-reviewed journal Frontiers in Physiology (Impact Factor 4.566), Research Topic entitled "Biological Mechanism-Based and Patient-Centered Management of Cancer-Related

Symptoms and Syndromes";

- Participation in the Editorial Board as Guest Editor of the Journal "Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry" within the Special Issue "Role of inflammation in the evolution of Cancer disease"; August 2011, 10 (4);

- Participation as Author in the AIOM Guidelines "Tumors of the elderly" Editions 2014, 2015, 2016, 2017, 2018, 2019, 2021. Publication in collaboration with SIOG, SIGOT and GIOGER. 2019 edition published in the National Guidelines System (SNLG) of the Istituto Superiore di Sanità (snlg.iss.it).

- Participation as Author of the AIOM guidelines on Neoplastic Cachexia "TREATMENT AND PREVENTION OF NEOPLASTIC CACHEXIA" from the 2012 edition to date. 2021 version published on the National Guidelines System (SNLG) of the Italian National Institute of Health (snlg.iss.it)

- Participation in the Editorial Committee of the treatise "Cancer anemia. Clinical implications, etiopathogenesis and therapeutic possibilities" Macciò A, Madeddu C, Mantovani G. Il Pensiero Scientifico Editore. December 2006;

- Collaboration as Reviewer for several international journals of recognized prestige with impact factor including:

The Lancet Healthy Longevity from 2023

Cancer Research from 19/04/2015 (Impact factor 12.701)

BMC Cancer since 04/11/2016 (Impact factor 4.430)

Frontiers in Oncology from 13/01/2019 (Impact factor 6.244)

Journal of Cachexia, Sarcopenia and Muscle from 25/05/2020 (Impact factor 12.910)

Frontiers in Nutrition since 2017 (Impact factor 6.576)

Cells from 23/12/2020 (Impact factor 6.600)

International Journal of Molecular Sciences from 01/04/2021 (Impact factor 5.924)

International Journal of Obesity from 02/06/2015 (Impact factor 5.095)

Frontiers in Physiology from 01/01/2017 (Impact Factor 4.566)

European Journal of Pharmacology from 15/12/2015 (Impact factor 4.432)

Journal of Clinical Medicine from 31/03/2020 (Impact factor 4.242)

Immunotherapy from 17/06/2021 (Impact factor 4.196)

Supportive Care Cancer from 06/03/2022 (Impact factor 3.603)

Awards and recognitions

- In 2021 Winner of the "Francesco Alziator" Award XIII Edition for the Medicine Category, Cagliari 8 December 2021, "for the research carried out in the field of tumors of the female genital apparatus and the study for the progress in the field of oncology of the treatment of patients suffering from pathologies that are difficult to resolve".

- Affiliation as "Emeritus Member" of the American Association for Cancer Research (AACR) since 01/01/1992, Affiliation with the University of Cagliari, Participation in the Research Groups: "Cancer Immunology (CIMM)"; "Tumor Microenvironment (TME)"; "Women in Cancer Research (WICR)".

- Affiliation as a Member of the Society of recognized international prestige "European Society for Medical Oncology (ESMO)" since 2015

- Affiliation as a Member of the Italian Association of Medical Oncology (AIOM)

- Membership of the Multinational Association of Supportive Care in Cancer (MASCC) since 2018

- Affiliation to the Italian Network of Support Care in Oncology Association - N.I.C.S.O. in 2018

CLINICAL, PROFESSIONAL, ORGANIZATIONAL AND MANAGERIAL ACTIVITIES

Since 01/07/2005 (18 years of service) he has been working as Medical Director in the discipline of oncology at the SC of Medical Oncology of the AOU of Cagliari at the Duilio Casula Polyclinic. With resolution no. 1268 adopted by the Director General, the positive assessment of the technical board of the professional activity carried out by the undersigned in assistance at the Medical Oncology Unit of the AOU, in possession of the requirement of professional seniority of more than five years from 01/07/2005 to 30/06/2020 (evaluation period of 15 years of activity) was approved.

Since September 2020 he has been Head of a High Specialization Assignment in "Multidisciplinary Management of Gynecological Neoplasms" lasting five years, a position still in progress (resolution no. 1087 of 03/09/2020 adopted by the Director General of the AOU Cagliari).

From 18/07/2022 to 31/05/2023 she was appointed Member as Clinician of the Independent Ethics Committee of the University Hospital (Resolution no. 667 adopted by the Director General of the University Hospital of Cagliari on 18.07.2022).

Prof. Clelia Madeddu carries out clinical-care activities at the S.C. of Medical Oncology both in hospitalization and Day Hospital and outpatient care; it also provides daytime standby service, night and holiday guard and on-call at the AUO of Cagliari.


In particular, Prof. Clelia Madeddu has carried out her activity at the Medical Oncology Day Hospital where she has personally followed about 2000 hospitalizations for oncological therapies (chemotherapy, biological treatments and target therapies, immunotherapy, hormone therapy, supportive therapy in the field of simultaneous and palliative care) in the last decade, dealing with:

- definition of integrated treatment pathways and administration of oncological therapies both in the adjuvant setting and in advanced oncological disease, within specific PDTAs by pathology;
- immunotherapy of solid tumors, in particular in the field of pulmonary, gynecological and melanoma neoplasms;
- innovative pharmacological therapies according to the internationally recognized criteria of appropriateness and in compliance with the prescription regulations in force;
- definition of targeted and personalized therapeutic approach based on genomic mutational profiling, integrated with histological and immunohistochemical profiling, where indicated on the basis of guidelines, PDTA pathways, and NHS Directives, developing the so-called precision medicine and mutational oncology;
- multidisciplinary and integrated treatment in particular of gynecological neoplasms, lung cancers, skin neoplasms and melanomas, sarcomas and rare tumors, in collaboration with the specialist colleagues involved (surgeons, gynecologists, dermatologists, radiation therapists) in the integrated multidisciplinary path both at intra-company and inter-company level;
- management of toxicities secondary to oncological treatments;
- definition of follow-up and screening pathway for both patients suffering from sporadic neoplasms and patients suffering from hereditary syndromes;
- planning of simultaneous care and palliative care through the definition of personalized intervention plans integrated with local structures and Home Care;
- integration of psychological support in the treatment of cancer patients, in collaboration with the psychological support service active at the Medical Oncology Unit of the AOU of Cagliari
- conducting and participating in clinical trials and research projects active at company level at the Oncology S.C.

Attached is a list of scientific publications in full

I authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003 n. 196 "code regarding the protection of personal data" and Regulation (EU) 2016/679 of 27 April 2016 (GDPR).

Cagliari 14/05/2025



List of the main scientific publications in extenso in international peer-reviewed journals

1. Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, Scartozzi M, Giglio S, Macciò A. Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. *Int J Mol Sci.* 2025; 26(5):2232.
Impact factor 4.9
2. Macciò A, Vallerino V, Sole G, Nemolato S, Giglio E, Madeddu C. Successful laparoscopic cytoreductive surgery for multiple (three) advanced recurrences of AGCT in a young woman. A case report. *Int J Surg Case Rep.* 2025;127:110960.
Impact factor 0.6
3. Macciò A, Madeddu C. Cancer is not a guest. *Transl Oncol.* 2025;51:102162.
Impact factor 4.5
4. Sardu C, Angius F, Contu P, Cosentino S, Deiana M, Fraschini M, **Madeddu C**, Massa E, Mereu A, Minerba L, Politi C, Puxeddu S, Salis F, Sinclair JMA, Agabio R. Raising awareness of alcohol as a modifiable risk factor for breast cancer: A randomized controlled trial comparing the efficacy of accessing an interactive website with a non-interactive website. *Breast.* 2025 Feb;79:103868.
Impact factor 5.7
5. Aviles Gonzalez CI, Galletta M, Sancassiani F, Cossu G, Trudu D, Urban A, Cantone E, Luchetta R, Nonnis M, Fragoso-Castilla P, Guerra Muñoz ME, Machado S, Nardi AE, Carta MG, **Madeddu C**. Healthcare students are faced with the issue of the rights of people with disabilities and the quality of services: Are we training future healthcare workers who overemphasize technology? *J Public Health Res.* 2024; 13(4):22799036241290262.
Impact factor 1.6
6. **Madeddu C**, Gramignano G, Lai E, Pinna G, Tanca L, Cherchi MC, Floris C, Farci D, Pretta A, Scartozzi M, Macciò A. Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors. *ESMO Open* 2024; 9(10):103738.
Impact factor 7.1
7. Cimbro E, Dessì M, Zirano P, **Madeddu C**, Atzori F, Lai E, Pretta A, Mariani S, Donisi C, Spanu D, Pozzari M, Murgia S, Saba G, Codipietro C, Palmas E, Sanna G, Semonella F, Sardo S, Finco G, Scartozzi M. Early taxane exposure and neurotoxicity in breast cancer patients. *Support Care Cancer.* 2024; 32(10):709.
Impact factor 2.8
8. Macciò A, Abis P, Sole G, D'Angelo N, Nemolato S, **Madeddu C**. A giant pelvic infiltrating schwannoma misdiagnosed as an ovarian neoplasm that was resected using a laparoscopic approach: A case report. *Int J Surg Case Rep.* 2024; 122:110138.
Impact factor 0.6
9. Carta MG, Cossu G, Primavera D, Aviles Gonzalez CI, Testa G, Stocchino S, Finco G, Littera MT, Deidda MC, Lorrai S, **Madeddu C**, Nardi AE, Sancassiani F. Heart Rate Variability Biofeedback Efficacy on Fatigue and Energy Levels in Fibromyalgia: A Secondary Analysis of RCT NCT0412183. *J Clin Med.* 2024; 13(14):4008.
Impact factor 3.0
10. Corrias G, Lai E, Zirano P, Mariani S, Donisi C, Liscia N, Saba G, Pretta A, Persano M, Fanni D, Spanu D, Balconi F, Loi F, Deidda S, Restivo A, Pusceddu V, Puzzone M, Solinas C, Massa E, **Madeddu C**, Gerosa C, Zorcolo L, Faa G, Saba L, Scartozzi M. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging. *Cancers (Basel).* 2024; 16(7):1364.
Impact factor 5.200
11. Donisi C, Pretta A, Pusceddu V, Zirano P, Lai E, Puzzone M, Mariani S, Massa E, **Madeddu C**, Scartozzi M. Immunotherapy and cancer: the multi-omics perspective. *Int J Mol Sci.* 2024; 25(6):3563
Impact factor 5.600
12. Abis P, **Madeddu C**, Magro Malosso G, Sole G, Mereu A, Locci G, Macciò A. Complicated enterocele: timely resolution with bowel resection via a vaginal approach: case report. *Front Surg.* 2023;10:1228981.
Impact factor 1.800

13. Macciò A, Sanna E, Piras R, Lavra F, Vallerino V, Maricosu G, Giglio E, Mura A, Tidore M, **Madeddu C**. Survival as a clinical outcome and its spiritual significance in a cohort of patients with advanced central pelvic neoplastic disease undergoing total pelvic exenteration: a poorly debated issue. *Front Med (Lausanne)*. 2023; 10:1173687 AM
Impact factor 5,058
14. Macciò A, **Madeddu C**. Molecular Basis and Advances in Targeted Immunotherapy for Cancer. *Int J Mol Sci*. 2023; 24(9):7802.
Impact factor 5,600
15. **Madeddu C**, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M, Macciò A. Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. *Cancers* 2023; 15:1076.
Impact 5,200
16. Macciò A, **Madeddu C**, Lai E, Scartozzi M. Cancer cachexia and chronic inflammation: an unbreakable bond. *Br J Cancer*. 2023; 128 (9):1609-1610
Impact factor 8,800
17. Bazzocchi A, Gazzotti S, Santarpia L, **Madeddu C**, Petroni ML, Aparisi Gómez MP. Editorial: Importance of body composition analysis in clinical nutrition. *Front Nutr*. 2023;9:1080636.
Impact factor 5,000
18. **Madeddu C**, Sanna E, Nemolato S, et al. Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report. *Diagnostics (Basel)*. 2022; 12(8):1910.
Impact factor 3,992
19. **Madeddu C**, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. *Int J Mol Sci*. 2022; 23(12):6489.
Impact factor 6,208
20. Mulas O, Mola B, **Madeddu C**, Caocci G, Macciò A, La Nasa G. Prognostic role of cell blood count in chronic myeloid neoplasm and acute myeloid leukemia and its possible implications in hematopoietic stem cell transplantation. *Diagnostics (Basel)*. 2022; 12(10):2493.
Impact factor 3,992
21. Maccio A, **Madeddu C**. Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Polen-De et al. *Int J Gynecol Cancer*. 2022; 32(11):1493.
Impact factor 4,800
22. Sanna E, **Madeddu C**, Lavra F, et al. Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series. *Int J Surg*. 2022;104:106744.
Impact factor 15,300
23. Maccio A, La Nasa G, Oppi S, **Madeddu C**. Defibrotide has a role in the therapy of COVID-19. Editorial for: Defibrotide therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS), *Chest*. 2022 Aug; 162(2):271-273
Impact factor 9,600
24. Massa E, Donisi C, Liscia N, **Madeddu C**, et al. The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review. *Clin Pract Epidemiol Ment Health*. 2021; 17(1):295-306.
Impact factor 0,805
25. Sanna E, Chiappe G, Lavra F, Nemolato S, Oppi S, Macciò A, **Madeddu C**. Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review. *Diagnostics*. 2022; 12(2):440.
Impact factor 3,992

26. Agabio R, **Madeddu C**, Contu P, Cosentino S, Deiana M, Massa E, Mereu A, Politi C, Sardu C, Sinclair JMA. Alcohol Consumption Is a Modifiable Risk Factor for Breast Cancer: Are Women Aware of This Relationship? *Alcohol Alcohol*. 2022; 57(5):533-539.
Impact factor 2.800
27. **Madeddu C**, Sanna E, Gramignano G, Tanca L, Cherchi MC, Mola B, Petrillo M, Macciò A. Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms. *Cancers* 2022; 14(2):268.
Impact factor 6.575
28. Macciò A, Donisi C, Sanna E, Chiappe G, Nemolato S, Melis L, Oppi S, Mola B, **Madeddu C**. Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. *Diagnostics* 2021; 11:2085.
Impact factor 3.992
29. Macciò A, **Madeddu C**. Potential role of macrophage activation in mediating thrombotic complications associated with the different vaccines against COVID-19. *Eur Rev Med Pharmacol Sci*. 2021; 25(20):6176-6178.
Impact factor 3.784
30. **Macciò A**, Sanna E, Lavra F, Chiappe G, Petrillo M, Madeddu C. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. *BMC Surg*. 2021; 21(1):380.
Impact factor 2.030
31. Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai MG, Macciò A, **Madeddu C**. Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. *Diagnostics (Basel)*. 2021; 11(7):1298.
Impact factor 3.992
32. Macciò A, Sanna E, Lavra F, Calò P, **Madeddu C**. Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports. *World J Clin Cases*. 2021 Jul 16; 9(20):5655-5660
Impact factor 1.534
33. **Madeddu C**, Neri M, Sanna E, Oppi S, Macciò A. Experimental drugs for chemotherapy- and cancer-related anemia. *J Exp Pharmacol*. 2021;13:593-611.
Impact factor 2.8
34. Macciò A, Sanna E, Neri M, Oppi S, **Madeddu C**. Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. *Int J Mol Sci*. 2021; 22(6):2890.
Impact factor 6.208
35. Macciò A, Oppi S, **Madeddu C**. COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? *J Ovarian Res*. 2021; 14(1):28.
Impact factor 5.506
36. Arends J, Strasser F, Gonella S, Solheim TS, **Madeddu C**, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, Ripamonti CI; ESMO Guidelines Committee. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆. *ESMO Open*. 2021; 6(3):100092.
Impact factor 6.883
37. Macciò A, Chiappe G, Kotsonis P, Lavra F, Sanna E, Collu I, Nemolato S, **Madeddu C**. Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5 kilograms to 11.000 kilograms. *Arch Gynecol Obstet*. 2021; 303(1):169-179.
Impact factor 2.493
38. Lai E, Astaro G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzone M, Pusceddu V, **Madeddu C**, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? *Crit Rev Oncol Hematol*. 2021;157:103167.

Impact factor 6.625

39. Cadeddu Dessalvi C, Deidda M, Noto A, **Madeddu C**, Cugusi L, Santoro C, López-Fernández T, Galderisi M, Mercurio G. Antioxidant approach as a cardioprotective strategy in chemotherapy-induced cardiotoxicity. *Antioxid Redox Signal*. 2021; 34:572-588
Impact factor 8.401
40. Macciò A, **Madeddu C**, Caocci G, Oppi S, La Nasa G. Defibrotide in the COVID-19 coagulopathy: what is the timing? *J Thromb Haemost*. 2020; 18(11):3113-3115.
Impact factor 5.824
41. Sanna E, **Madeddu C**, Melis L, Nemolato S, Macciò A. Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report. *World J Clin Cases* 2020; 8(16):3527-3533.
Impact factor 1.337
42. Macciò A, **Madeddu C**, Caocci G, La Nasa G. Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? *J Thromb Haemost*. 2020; 18:3106-3108
Impact factor 5.824
43. Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L, **Madeddu C**. Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. *Ski Rep*. 2020; 10(1):6096.
Impact factor 4.380
44. Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Zirano P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, **Madeddu C**, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. *Cancers (Basel)*. 2020; 12(5):1214.
Impact factor 6.639
45. Macciò A, **Madeddu C**. Blocking inflammation to improve immunotherapy of advanced cancer. *Immunology*. 2020; 159(4):357-364. doi: 10.1111/imm.13164
Impact factor 7.397
46. Macciò A, Kotsonis P, Aste L, Voicu MA, **Madeddu C**, Conti C, Camparini S. An interdisciplinary approach for laparoscopic removal of a large retroperitoneal pelvic schwannoma attached to vital vessels: A case report. *Medicine (Baltimore)*. 2019; 98(51):E18149
Impact factor 1.552
47. Macciò A, Chiappe G, Kotsonis P, Lavra F, Nieddu R, Onnis P, Sanna E, Mais V, **Madeddu C**. The utility of fibrinogen level as a predictor of complications after laparoscopic gynecologic surgery: a perspective observational study. *Gynecological Surgery* 2019; 16(1):11
Impact factor 0.570
48. Macciò A, Chiappe G, Lavra F, Sanna E, Nieddu R, **Madeddu C**. Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated polycythemia: A case report. *World Journal of Clinical Cases* 2019; 7: 3027-3032
Impact factor 1,100
49. Macciò A, Chiappe G, Lavra F, Sanna E, **Madeddu C**. Removal of a Huge Uterine Mass, Weighing 11000 Grams, In an Elderly Woman with a Minimally Invasive Surgical Approach: Feasibility and Safety. *Clinics in Oncology* 2019; 4: 1596. Doi: 10.25107/2474-1663.id1596
Impact factor 1.970
50. Macciò A, **Madeddu C**. The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. *Int J Cancer*. 2019; 145(9):2594-2596.
Impact factor 5.145
51. **Madeddu C**, Kotsonis P, Lavra F, Chiappe G, Melis L, Mura E, Scartozzi M, Macciò A. Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. *Oncotarget*. 2019; 10(21):2012-2021.

Impact factor 5.168

52. Neri M, Peiretti M, Melis GB, Piras B, Vallerino V, Paoletti AM, **Madeddu C**, Scartozzi M, Mais V. Systemic therapy for the treatment of endometrial cancer. *Expert Opin Pharmacother.* 2019; 20(16):2019-2032. doi: 10.1080/14656566.2019.1654996.

Impact factor 3,200

53. Macciò A, Busquets S, **Madeddu C**, Argilés JM. Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes. *Front Physiol.* 2018;9:1819.

Impact factor 4,000

54. **Madeddu C**, Gramignano G, Astarà G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Front Physiol.* 2018;9:1294.

Impact factor 4,000

55. Macciò A, **Madeddu C**. Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas. *JAMA Oncol.* 2018; 4(8):1134.

Impact factor 28,400

56. **Madeddu C**, et al. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6. *Haematological.* 2018; 103(9):E388-E391

Impact factor 10,100

57. Macciò A, Kotsonis P, Lavra F, Chiappe G, Mura E, Melis L, **Madeddu C**. A PET-positive rapidly growing mass of the abdominal wall after cesarean section with an unexpected diagnosis of vernix caseosa granuloma: a case report. *Gynecol Surg.* 2018; 15(1):17. DOI: 10.1186/s10397-018-1050-8

Impact Factor 0.570

No. of Citations: 2

58. Macciò A, **Madeddu C**, Kotsonis P, Chiappe G, Lavra F, Collu I, Demontis R. Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of emblematic cases. *Gynecol Surg.* 2018; 15(1):6; doi: 10.1186/s10397-018-1037-5. PMID: 29568253

Impact factor 0.570

59. Argilés JM, Betancourt A, Guàrdia-Olmos J, Peró-Cebollero M, López-Soriano FJ, **Madeddu C**, Serpe R, Busquets S. Validation of the CAchexia SCORE (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. *Front Physiol.* 2017; 17; 8:92; doi: 10.3389/fphys.2017.00092. PMID: 28261113

Impact Factor 4,000

60. Macciò A, Chiappe G, Kotsonis P, Lavra F, Serra M, Demontis R, **Madeddu C**. Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report. *Int J Surg Case Rep.* 2017; 38:107-110; doi: 10.1016/j.ijscr.2017.07.020.

Impact Factor 0.600

61. Angius F, Piras E, Uda S, **Madeddu C**, Serpe R, Bigi R, Chen W, Dittmer DP, Pompei R, Ingianni A. Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation. *Journal of Antibiotics.* 2017; 70(9):962-966; doi: 10.1038/ja.2017.67.

Impact factor 3,300

62. Pani F, Massidda M, Pusceddu V, Puzzone M, Massa E, **Madeddu C**, Scartozzi M, Mariotti S. Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? *Eur J Endocrinol.* 2017; 177 (1): 85-92; doi: 10.1530/EJE-17-0231. PMID: 28468766

Impact Factor 5,800

63. Macciò A, Kotsonis P, Lavra F, Chiappe G, Sanna D, Zamboni F, **Madeddu C**. Laparoscopic removal of a very large uterus weighting 5320 g is feasible and safe: a case report. *BMC SURGERY* 2017; 17 (50); doi: 10.1186/s12893-017-0248-4. PMID: 28472966

Impact Factor 1,900

64. Antoni G, Marini E, Curreli N, Tuveri V, Comandini O, Cabras S, Gabba S, **Madeddu C**, Crisafulli A, Rinaldi AC. Energy expenditure in caving. PLoS One. 2017; 12(2):E0170853. doi: 10.1371/journal.pone.0170853.
Impact factor 3,700
65. Cadeddu C, Piras A, Dessi M, **Madeddu C**, Mantovani G, Scartozzi M, Hagendorff A, Colonna P, Mercurio G. Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy. Int J Cardiovasc Imaging. 2017; 33(2):197-207. doi: 10.1007/s10554-016-0987-9. PMID: 27696298
Impact Factor 2,100
66. **Madeddu C**, Deidda M, Piras A, Cadeddu C, Demurtas L, Puzzone M, Piscopo G, Scartozzi M, Mercurio G. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown). 2016; 17 (Suppl 1 Special issue on Cardiotoxicity from Antiplastic Drugs and Cardioprotection):e12-e18. doi: 10.2459/JCM.0000000000000376. PMID: 27755238
Impact factor 3,000
67. Macciò A, Lavra F, Chiappe G, Kotsonis P, Sollai G, Zamboni F, **Madeddu C**. Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman. J Obstet Gynaecol. 2016; 36(8):1012-1015; doi: 10.1080/01443615.2016.1234444. PMID: 27750462
Impact Factor 1,300
68. Macciò A, Kotsonis P, Chiappe G, Melis L, Zamboni F, **Madeddu C**. Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up. J Minim Invasive Gynecol. 2016; 23(6):1003-8; DOI: 10.1016/J.JMIG.2016.05.005. PMID: 27234428
Impact factor: 4,100
69. Macciò A, Chiappe G, Kotsonis P, Nieddu R, Lavra F, Serra M, Onnis P, Sollai G, Zamboni F, **Madeddu C**. Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures. Arch Gynecol Obstet. 2016; 294(3):525-31. doi: 10.1007/s00404-016-4075-0. PMID: 27016346
Impact factor: 2,600
70. Orgiano L, Pani F, Astara G, **Madeddu C**, Marini S, Manca A, Mantovani G. The role of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience. Support Care Cancer. 2016; 24(10):4293-9. doi: 10.1007/s00520-016-3262-7.
Impact factor: 3,100
71. **Madeddu C**, Mantovani G, Gramignano G, Macciò A. Advances in pharmacologic strategies for cancer cachexia. Expert Opin Pharmacother. 2015; 16(14):2163-77. doi: 10.1517/14656566.2015.1079621. PMID: 26330024
Impact factor 3.889
72. **Madeddu C**, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncol. 2015; 11(19):2697-2710. DOI: 10.2217/fon.15.195. PMID: 26376740
Impact factor: 3,300
73. Macciò A, Gramignano G, **Madeddu C**. A Multi-Targeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer. J Pain Symptom Manage. 2015; 50(2):e1-4. doi: 10.1016/j.jpainsymman.2015.04.014. PMID: 26004402
Impact factor 4,700
74. Angius F, Spolitu S, Uda S, Deligia S, Frau A, Banni S, Collu M, Accossu S, **Madeddu C**, Serpe R, Batetta B. High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts. Ski Rep. 2015;5:17812. doi: 10.1038/srep17812.
Impact factor 5.133

75. Madonna R, Cadeddu C, Deidda M, Giricz Z, **Madeddu C**, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Varga ZV, Zito C, Geng YJ, Mercurio G, Ferdinandy P. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. *Int J Cardiol.* 2015;191:203-10. doi: 10.1016/j.ijcard.2015.04.232. PMID: 25974196
Impact factor 4,164
76. Macciò A, Gramignano G, **Madeddu C**. Surprising results of a supportive integrated therapy in myelofibrosis. *Nutrition.* 2015;31:239-43. doi: 10.1016/j.nut.2014.07.016. PMID: 25466670
Impact factor 4,400
77. Cotti E, Zedda A, Deidda M, Piras A, Flore G, Ideo F, **Madeddu C**, Pau VM, Mercurio G. Endodontic infection and endothelial dysfunction are associated with different mechanisms in men and women. *J Endod.* 2015; 41(5):594-600. doi: 10.1016/j.joen.2015.01.037
Impact factor 4,200
78. Macciò A, **Madeddu C**, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematological.* 2015; 100(1):124-32. doi: 10.3324/haematol.2014.112813. PMID: 25239265
Impact factor 10,100
79. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators (... **Madeddu C**..). Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2015; 16(5):583-94.
Impact factor 51,100
80. **Madeddu C**, Gramignano G, Floris C, Murenu G, Sollai G, Macciò A. The role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. *J Cell Mol Med.* 2014; 18(12):2519-29. DOI: 10.1111/JCMM.12413. PMID: 25338520
Impact factor 5,310
81. **Madeddu C**, Gramignano G, Kotsonis P, Paribello F, Macciò A. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases. *Oncol Lett.* 2014; 8(3):1279-1282. doi: 10.3892/ol.2014.2319. PMID: 25120706
Impact Factor 2,900
82. Macciò A, **Madeddu C**, Kotsonis P, Pietrangeli M, Paoletti AM. Large twisted ovarian fibroma associated with Meigs' syndrome, abdominal pain and severe anemia treated by laparoscopic surgery. *BMC Surg.* 2014;14:38. doi: 10.1186/1471-2482-14-38. PMID: 24962423
Impact factor 2,590
83. Macciò A, **Madeddu C**, Kotsonis P, Pietrangeli M, Paoletti AM. Successful laparoscopic management of a giant ovarian cyst. *J Obstet Gynaecol.* 2014; 34(7):651-2. doi: 10.3109/01443615.2014.902432. PMID: 24786285
Impact factor 1,300
84. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; "FOLLOW-UP" Study Group (...**Madeddu C**..). Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. *PLoS One.* 2014; 9(4):E94063. doi: 10.1371/journal.pone.0094063.
Impact factor 3,700
85. Macciò A, **Madeddu C**. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-a review. *J Mol Med (Berl).* 2013; 91(12):1355-68. doi: 10.1007/s00109-013-1080-7. PMID: 24057813
Impact Factor 4,768
86. Ribuffo D, Atzeni M, Guerra M, Bucher S, Politi C, Deidda M, Atzori F, Dessi M, **Madeddu C**, Lay G. Treatment of irradiated expanders: protective lipofilling allows immediate prosthetic breast reconstruction in the setting of postoperative radiotherapy. *Aesthetic Plast Surg.* 2013; 37(6):1146-52. doi: 10.1007/s00266-013-0221-2.
Impact Factor 2,400

87. Macciò A, **Madeddu C**. Cisplatin : an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. *Expert Opin Pharmacother*. 2013; 14(13):1839-57. doi: 10.1517/14656566.2013.813934. PMID: 23876094
Impact Factor 3,200
88. Dessì M, **Madeddu C**, Piras A, Cadeddu C, Antoni G, Mercurio G, Mantovani G. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. *Springerplus*. 2013; 2(1):198. doi: 10.1186/2193-1801-2-198. PMID: 23741643
Impact Factor 1.130
89. Macciò A, **Madeddu C**. Management of anemia of inflammation in the elderly. *Anaemia*. 2012;2012:563251. doi: 10.1155/2012/563251. PMID: 23091709
Impact factor 2,900
90. Mantovani G, **Madeddu C**, Macciò A. Cachexia and Oxidative stress in cancer: an innovative therapeutic management. *Curr Pharm Des*. 2012; 18(31):4813-8. PMID: 22632861
Impact Factor 3.311
91. Macciò A, **Madeddu C**, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. *Gynecol Oncol*. 2012; 124(3):417-25. doi: 10.1016/j.ygyno.2011.12.435. PMID: 22198049
Impact Factor 4,700
92. **Madeddu C**, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. *Clin Nutr* 2012;31:176-82. doi: 10.1016/j.clnu.2011.10.005. PMID: 22047681
Impact Factor 6,300
93. Macciò A, **Madeddu C**, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. *Expert Opin Pharmacother*. 2012; 13(17):2453-72. doi: 10.1517/14656566.2012.734297. PMID: 23072481
Impact Factor 3,200
94. Macciò A, **Madeddu C**. Inflammation and ovarian cancer. *Cytokine*. 2012; 58(2):133-47. doi: 10.1016/j.cyto.2012.01.015. PMID: 22349527
Impact Factor 3,800
95. Macciò A, **Madeddu C**, Kotsonis P, Caffiero A, Desogus A, Pietrangeli M, Paoletti AM. Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. *Arch Gynecol Obstet*. 2012; 286(5):1209-14 doi: 10.1007/s00404-012-2441-0. PMID: 22752596
Impact Factor 2,600
96. Macciò A, **Madeddu C**, Caffiero A, Paoletti AM. Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach. *Arch Gynecol Obstet*. 2012; 285(6):1577-80. doi: 10.1007/s00404-011-2197-y. PMID: 22207499
Impact Factor 2,600
97. Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, **Madeddu C**, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM. L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. *Clin Nutr*. 2012; 31(6):889-95. doi: 10.1016/j.clnu.2012.03.005. PMID: 22608917
Impact Factor 6,300
98. **Madeddu C**, Macciò A, Mantovani G. Multitargeted treatment of cancer cachexia. *Crit Rev Oncog*. 2012; 17(3):305-14. PMID: 22831161
Impact factor 3.364
99. Dessì M, Piras A, **Madeddu C**, Cadeddu C, Deidda M, Massa E, Antoni G, Mantovani G, Mercurio G. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. *Exp Ther Med*. 2011; 2(5):1003-1009. DOI: 10.3892/etm.2011.305. PMID: 22977612.

Impact Factor 2,700

100. Cotti E, Dessì C, Piras A, Flore G, Deidda M, **Madeddu C**, Zedda A, Longu G, Mercurio G. Association of endodontic infection with detection of an initial lesion to the cardiovascular system. *J Endod.* 2011; 37(12):1624-9. doi: 10.1016/j.joen.2011.09.006. PMID: 22099894

Impact Factor 4,200

101. Macciò A, **Madeddu C**. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. *ScientificWorldJournal.* 2011;11:2020-36. doi: 10.1100/2011/806787. PMID: 22125453

Impact Factor 1.524

102. **Madeddu C**, Macciò A, Mantovani G. Metabolic changes in cancer patients. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry.* 2011; 10 (4): 281-285

Impact Factor 0.280

103. Mantovani G, Macciò A, **Madeddu C**, Serpe R, Gramignano G, Panzone F. Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients. *Current Trends in Immunology* 2011; 11:65-74

Impact factor 0.120

104. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, **Madeddu C**, Massa E, Mercurio G. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. *Am Heart J.* 2010; 160(3):487.e1-7. doi: 10.1016/j.ahj.2010.05.037. PMID: 20826257

Impact Factor 5.052

105. Macciò A, **Madeddu C**, Chessa P, Panzone F, Lissoni P, Mantovani G. Oxytocin is able both to increase peripheral blood lymphomonocytes proliferative response to phytohemagglutinin and reverse the immunosuppressive oestrogen activity. *IN VIVO;* 2010; 24:157-164. PMID: 20363988

Impact Factor 2,300

106. Maccio A, **Madeddu C**, et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. *J Mol Med* 2010; 88:677-686. doi: 10.1007/s00109-010-0611-8. PMID: 20339829

Impact Factor 5.192

107. Macciò A, **Madeddu C**, Gramignano G, et al. Efficacy and safety of oral lactoferrin supplementation associated with rHuEPO beta for the treatment of anemia in advanced cancer patients submitted to chemotherapy: open-label, randomized controlled study. *Oncologist* 2010; 15:894-902. doi: 10.1634/theoncologist.2010-0020. PMID: 20647390

Impact Factor 5.826

108. Mantovani G, Macciò A, **Madeddu C**, Serpe R, Antoni G, Massa E, Dessì M, Panzone F. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. *J Mol Med.* 2009;88:85-92. doi: 10.1007/s00109-009-0547-z. PMID: 19802504

Impact Factor 5.004

109. Mantovani G, Macciò A, **Madeddu C**, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia. *Oncologist* 2010; 15:200-11. doi: 10.1634/theoncologist.2009-0153. PMID: 20156909

Impact Factor 5.826

110. Mantovani G, **Madeddu C**, Serpe R. Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients. *Curr Opin Support Palliat Care.* 2010; 4(4):259-65. doi: 10.1097/SPC.0b013e32833b35c0. PMID: 20531198

Impact factor 2,100

111. Mantovani G, **Madeddu C**. Cancer cachexia: medical management. *Support Care Cancer.* 2010; 18(1):1-9. doi: 10.1007/s00520-009-0722-3. PMID: 19688225

Impact Factor 3,100

112. **Madeddu C**, Mantovani G. An update on promising agents for the treatment of cancer cachexia. *Curr Opin Support Palliat Care*. 2009; 3(4):258-62. doi: 10.1097/SPC.0b013e3283311c6f. PMID: 19667995
Impact factor 2,100
113. Macciò A, **Madeddu C**, Chessa P, Mantovani G, Galanello R. Use of erythropoiesis agents for the treatment of anemia and related fatigue in a pregnant woman with HbH disease. *Br J Haematol*. 2009;146:335-7. doi: 10.1111/j.1365-2141.2009.07755.x. PMID: 19466977
Impact Factor 6,500
114. Macciò A, **Madeddu C**, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. *Obes Rev*. 2009; 10(6):660-70. doi: 10.1111/j.1467-789X.2009.00592.x. PMID: 19460113
Impact Factor 8,900
115. Macciò A, **Madeddu C**, Panzone F, Mantovani G. Carbocysteine : clinical experience and new perspectives in the treatment of chronic inflammatory diseases. *Expert Opin Pharmacother* 2009;10:693-703. doi: 10.1517/14656560902758343. PMID: 19239402
Impact Factor 3,200
116. **Madeddu C**, Macciò A, Astarà G, Massa E, Dessì M, Antoni G, Panzone F, Serpe R, Mantovani G. Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. *Mediterranean Journal of Nutrition and Metabolism*. 2010; 3 (2): 165-172.
Impact factor 1,100
117. **Madeddu C**, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. *Expert Opin Pharmacother*. 2009;10:1359-66. doi: 10.1517/14656560902960162. PMID: 19445562
Impact Factor 3,200
118. Tanca FM, **Madeddu C**, Macciò A, Serpe R, Panzone F, Antoni G, Massa E, Astarà G, Mantovani G. New perspective on the nutritional approach to cancer-related anorexia/cachexia. Preliminary results of a randomized phase III clinical trial with five different arms of treatment. *Mediterranean journal of nutrition and metabolism* 2009; 2(1): 29-36.
Impact factor 1,100
119. Macciò A, **Madeddu C**, Massa D, Astarà G, Farci D, Melis GB, Mantovani G. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. *J Cell Mol Med* 2009; 13(9B):3951-9. doi: 10.1111/j.1582-4934.2008.00408.x. PMID: 18624749
Impact Factor 5,300
120. Macciò A, **Madeddu C**, Sanna E, Panzone F, Volpe A, Mantovani G. Evidence that human serum with high levels of estrogens interfere with immune system both by decreasing CD25 expression on T-cell and by increasing interleukin-2 availability. *Reprod Sci*. 2008;15:961-9. doi: 10.1177/1933719108322428. PMID: 19050329
Impact Factor 2,900
121. Mantovani G, **Madeddu C**, Cadeddu C, Dessì M, Piras A, Massa E, Serpe R, Antoni G, Mercurio G. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. *Oncologist*. 2008;13:1296-305. doi: 10.1634/theoncologist.2008-0151. PMID: 19060235
Impact Factor 6.630
122. Mantovani G, **Madeddu C**. Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. *Curr Opin Support Palliat Care*. 2008; 2(4):275-81. PMID: 19069312
Impact factor 2,100
123. Massa E, Astarà G, **Madeddu C**, Dessì M, Loi C, Lepori S, Mantovani G. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response. *Crit Rev Oncol Hematol*. 2009; 70(1):83-91. doi: 10.1016/j.critrevonc.2008.07.002. PMID: 18723369
Impact Factor 6,200

124. Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M, Gabbas A, Serpe R, **Madeddu C**, Scarpa A, Cocco P. Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukemia. *Hematol Oncol*. 2008; 26(2):98-103. doi: 10.1002/hon.843. PMID: 18271063
Impact Factor 3,300
125. Mantovani G, Macciò A, **Madeddu C**, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P, Floris C. Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results. *Nutrition* 2008; 24: 305-313. doi: 10.1016/j.nut.2007.12.010. PMID: 18262758
Impact Factor 4,400
126. Massa E, **Madeddu C**, Astarà G, Pisano M, Spiga C, Tanca FM, Sanna E, Puddu I, Patteri E, Lamonica G, Deiana L, Saba F, Mantovani G. An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: Results of a phase II open study. *Crit Rev Oncol Hematol* 2008; 66: 75-83. doi: 10.1016/j.critrevonc.2007.11.002. PMID: 18164209
Impact Factor 6,200
127. Mantovani G, **Madeddu C**, Gramignano G, Serpe R, Massa E, Deiana L, Macciò A. An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: background and design of an ongoing, phase III, randomized clinical trial. *Support Cancer Ther* 2007; 4:163-167. doi: 10.3816/SCT.2007.n.011. PMID: 18632483
128. Mantovani G, **Madeddu C**, Macciò A, Massa E, Gramignano G and Serpe R. Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia. *Current Nutrition & Food Science* 2007;3:184-193.
Impact factor 0.900
129. Mercurio G, Cadeddu C, Piras A, Dessì M, **Madeddu C**, Deidda M, Serpe R, Massa E, Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. *Oncologist*. 2007;12:1124-33. DOI: 10.1634/theoncologist.12-9-1124. PMID: 17914082
Impact Factor 5,800
130. Sanna F, Bonatesta RR, Frongia B, Uda S, Banni S, Melis MP, Collu M, **Madeddu C**, Serpe R, Puddu S, Porcu G, Dessì S, Batetta B. Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. *J Vasc Res*. 2007;44:253-63. PMID: 17361089
Impact Factor 2.463
131. Mantovani G, Macciò A, **Madeddu C**, Gramignano G, Lusso MR, Serpe R, Massa E, Astarà G, Deiana L. A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmacoenutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress. *Cancer Epidemiol Biomarkers Prev*. 2006;15:1030-4. DOI: 10.1158/1055-9965.EPI-05-0538. PMID: 16702388
Impact Factor 4,200
132. Gramignano G, Lusso MR, **Madeddu C**, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astarà G, Macciò A, Mantovani G. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition*. 2006; 22:136-45. doi:10.1016/j.nut.2005.06.003. PMID: 16459226
Impact Factor 4,400
133. Massa E, **Madeddu C**, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. *Crit Rev Oncol Hematol*. 2006;57:175-82. DOI: 10.1016/j.critrevonc.2005.06.001. PMID: 16213740
Impact Factor 6,200
134. Macciò A, **Madeddu C**, Massa D, Mudu MC, Lusso MR, Gramignano R, Serpe R, Melis GB, Mantovani G. Hemoglobin levels correlate with Interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood* 106:362-367, 2005. DOI: 10.1182/blood-2005-01-0160. PMID: 15774616
Impact Factor 20,300

135. Mantovani G, Macciò A, **Madeddu C**, Serpe R, Massa E, Gramignano G, Lusso MR, Curreli N, Rinaldi A. Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity. *J Exp Ther Oncol*. 2004;4:69-78. PMID: 15255293
Impact factor 0.110
136. Mantovani G, **Madeddu C**, Macciò A, Gramignano G, Lusso MR, Massa E, Astarà G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. *Cancer Epidemiol Biomarkers Prev*. 2004; 13:1651-9. PMID: 15466983
Impact Factor 4,500
137. Mantovani G, **Madeddu C**, Gramignano G, Ferreli L, Massa E, Contu P, Serpe R. Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients. *Oncol Rep*. 2004; 11:197-206. PMID: 14654926
Impact Factor 4,200
138. Mantovani G, Macciò A, **Madeddu C**, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. *J Mol Med*. 2003; 81: 664-673. DOI: 10.1007/s00109-003-0476-1. PMID: 12928788
Impact Factor 4,700
139. Mantovani G, Macciò A, **Madeddu C**, Massa E. Cancer-related cachexia and oxidative stress: beyond current therapeutic options. *Expert Rev Anticancer Ther*. 2003; 3: 381–392. PMID: 12820780 DOI: 10.1586/14737140.3.3.381
Impact Factor 3,300
140. Mantovani G, Macciò A, **Madeddu C**, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. *Free Radic Res*. 2003; 37: 213-223. PMID: 12653210.
Impact Factor 3,300
141. Mantovani G, Macciò A, **Madeddu C**, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L. Reactive oxygen species, antioxidant mechanisms, and serum cytokines levels in cancer patients: impact of an antioxidant treatment. *J Environ Pathol Toxicol Oncol*. 2003; 22(1):17-28. PMID: 12678402
Impact factor 2,400
142. Mantovani G, **Madeddu C**, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astarà G, Macciò A, Serpe R. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life and laboratory parameters. *J Exp Ther Oncol*. 2003; 3(4):205-19. PMID: 14567291
Impact Factor 0.110
143. Mantovani G, Massa E, Astarà G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, **Madeddu C**, Mura L, Mudu MC, Proto E, Tore G, Mura M, Macciò A, Ferreli A, Amichetti M. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: A phase II study with organ-sparing purposes. *Oncol Rep*. 2003; 10(3):759-66. PMID: 12684655
Impact Factor 4,200
144. Mantovani G, Massa E, Astarà G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, **Madeddu C**, Macciò A. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: An evaluation of effectiveness, safety and costs. *Oncol Rep*. 2003; 10(1):197-206. PMID: 12469169
Impact factor 4,200
145. Mantovani G, Massa E, Ferreli L, Astarà G, **Madeddu C**, Gramignano G, Lusso MR. Efficacy, compliance and prognostic significance of a comprehensive geriatric assessment in the geriatric cancer patient. *Geriatric and Medical Intelligence* 2003; 12 (1): 33- 41.
Impact factor 0.101

146. G. Mantovani, A. Macciò, **C. Madeddu**, L. Mura, E. Massa, G. Gramignano, M.R. Lusso, V. Murgia, P. Camboni, L. Ferrelli. Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. *J Cell Mol Med.* 2002 Oct-Dec; 6(4):570-82. PMID: 12611641
Impact Factor 5,300
147. Mantovani G, Macciò A, **Madeddu C**, Mulas C, Massa E, Astarà G, Ferrelli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L. Phase II Study of subcutaneously administered Interleukin 2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer patients responders to previous chemotherapy. *Oncol Rep.* 2002; 9(4):887-96. PMID: 12066227
Impact Factor 4,200
148. Mantovani G, Macciò A, Mulas C, Massa E, **Madeddu C**, Mura L, Contu P, Versace R. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in Stage IIIB-IV non-small cell lung cancer. *Oncol Rep.* 2002; 9(3):661-70. PMID: 11956647
Impact Factor 4,200
149. Mantovani G, Macciò A, **Madeddu C**, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferrelli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. *Int J Cancer.* 2002; 98(1):84-91. PMID: 11857390
Impact Factor 6,400
150. Mantovani G, Proto E, Massa E, Mulas C, **Madeddu C**, Mura L, Mudu MC, Astarà G, Murgia V, Gramignano G, Ferrelli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Amichetti M, Maccio A. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. *Int J Oncol.* 2002; 20(2):419-27. PMID: 11788911.
Impact Factor 5,200
151. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Astarà G, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferrelli L. Anorexia/Cachexia and oxidative stress in cancer patients. *Italian Journal of Parenteral and Enteral Nutrition* 2003; 21(2):82-86
Impact factor 0.104
152. Mantovani G, Macciò A, **Madeddu C**, Mura L, Massa E, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Ferrelli L. Role of proinflammatory cytokines and leptin in cancer-related anorexia/cachexia. Metabolic abnormalities and therapeutic approaches. *Italian Journal of Parenteral and Enteral Nutrition* 2002; 20(1): 13-20
Impact factor 0.104
153. Mantovani G, Maccio A, **Madeddu C**, Massa E, Mudu MC, Mulas C, Gramignano G, Massidda S, Murgia V, Lusso MR, Mura L. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy. *Int J Oncol.* 2001; 18(2):383-91. PMID: 11172608
Impact Factor 5,200
154. Mantovani G, Macciò A, **Madeddu C**, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. *J Mol Med (Berl).* 2001; 79(7):406-14. PMID: 11466563
Impact Factor 4,700
155. Mantovani G, Macciò A, Massa E, **Madeddu C**. Managing Cancer-Related Anorexia/Cachexia. *Drugs* 2001; 61; 499-514.
Impact Factor 11,500
156. Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, **Madeddu C**, Dessì A. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. *J Mol Med (Berl).* 2000; 78(10):554-61. PMID: 11324680
Impact Factor 4,700

157. Bozzetti F, Mariani L, Lo Vullo S; SCRINIO Working Group (**Madeddu C among collaborators**), Amerio ML, Biffi R, Caccialanza G, Capuano G, Correja I, Cozzaglio L, Di Leo A, Di Cosmo L, Finocchiaro C, Gavazzi C, Giannoni A, Magnanini P, Mantovani G, Pellegrini M, Rovera L, Sandri G, Tinivella M, Vigevani E. The nutritional risk in oncology: a study of 1,453 cancer outpatients. *Support Care Cancer*. 2012; 20(8):1919-28. doi: 10.1007/s00520-012-1387-x.

Impact factor 3,100

158. Sketches F; SCRINIO Working Group (**Madeddu C among collaborators**). Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. *Support Care Cancer*. 2009; 17(3):279-84. doi: 10.1007/s00520-008-0476-3. PMID: 18581148

Impact factor 3,100

159. Serpe R, Demurtas L, Puzzone M, Madeddu C, Scartozzi M. Cancer cachexia assessment: new tools for oncologists | [The evaluation of neoplastic cachexia in clinical practice: new tools for the oncologist]. *Recent advances in medicine* 2016; 107(10): 515-524

Impact Factor 0.172

160. Cugusi L, Solla P, Serpe R, Pilia K, Pintus V, **Madeddu C**, Bassareo PP, Mercurio G. Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: A pilot study. *Sports Medicine* 2015; 68: 473-485.

Impact factor 0.600

CHAPTERS OF INTERNATIONAL BOOKS

- Mantovani G and Madeddu C. Oxidative Stress and Cancer Cachexia (chapter 25). In: *Oxidative Stress, Disease and Cancer*. Singh K.K. ed., Imperial College Press, London, 2006, pp 733-759.

- Mantovani G and Madeddu C. Cancer progression and alpha-tocopherol in relation with other antioxidants. In: *The Encyclopedia of Vitamin E*, Victor Preedy and Ronald Watson (Eds), CABI Publishing, Wallingford, Oxon, UK, 2007, pp 886-894

- Mantovani G and Madeddu C. Epidemiology of cachexia. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 39-43.

- Madeddu C and Mantovani G. Immunological parameters of nutrition. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 111-124.

- Mantovani G and Madeddu C. Cachexia related to multiple causes. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 161-162.

- Macciò A, Madeddu C and Mantovani G. Glucose metabolism. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 195-203.

- Mantovani G and Madeddu C. Proinflammatory cytokines: their role in multifactorial cancer cachexia. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 477-482.

- Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astaro G, Serpe R. A phase II study with antioxidants, both in the diet and supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 685-698.

- Mantovani G, Macciò A, Madeddu C, Gramignano G. L-carnitine supplementation on quality of life and other health measures. In: *"Handbook of Disease Burden and Quality of Life Measures"*, Springer, May 22 2008